Eloxx Pharmaceuticals, Inc. — Form 8-K
Filed October 21, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Eloxx Pharmaceuticals filed an 8-K on October 22, 2026, reporting Item 5.02 events concerning departure of directors or officers and compensatory arrangements. The filing references Item 8.01 (Other Events) but the specific details of which officers departed, their roles, compensation amounts, and the nature of arrangement changes are not provided in the document metadata or accessible text. No dollar amounts, dates of departure, or names of affected parties are disclosed in the materials shown.
Why this rating
Without specific officer names, roles, or dollar amounts, cannot assess materiality. For a $330K market-cap micro-cap, even routine departures could matter, but filing lacks concrete details needed to evaluate impact.
Extracted items
- 5.02 exec change
- 8.01 other event
See more from October 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.